Healthcare systems across the Middle East and Africa (MEA) are undergoing a critical transformation as governments and private players invest in early disease detection and diagnostic accuracy. At the center of this shift lies the Middle East and Africa in-vitro diagnostics (IVD) market, which plays a vital role in identifying infectious diseases, chronic conditions, and genetic disorders. Growing public health challenges and the need for timely diagnosis are accelerating the adoption of advanced IVD technologies across the region.

Market Overview

The Middle East and Africa in-vitro diagnostics market was valued at USD 2.62 Billion in 2025. Supported by improving healthcare access and laboratory modernization, the market is projected to grow at a CAGR of 3.20% from 2026 to 2035, reaching an estimated value of USD 3.59 Billion by 2035.

In-vitro diagnostics include reagents, instruments, and software used to analyze blood, tissue, and other biological samples. These solutions are essential for disease screening, treatment monitoring, and outbreak control, particularly in regions facing a high prevalence of infectious diseases.

Key Market Drivers

Several factors are contributing to the expansion of the MEA IVD market:

Rising infectious disease burden: High incidence of HIV, tuberculosis, hepatitis, and emerging viral infections continues to drive demand for reliable diagnostic tests.

Improving regulatory oversight: Strengthening of regulatory frameworks in countries such as Saudi Arabia, the UAE, and South Africa is enhancing product quality and market confidence.

Investments in laboratory infrastructure: Government-led healthcare reforms and private sector investments are expanding diagnostic laboratories and hospital testing capabilities.

Growing awareness of early diagnosis: Increased emphasis on preventive healthcare and routine testing is improving test adoption rates.

Technology and Segment Insights

Immunoassays, molecular diagnostics, and clinical chemistry tests dominate the market due to their widespread use in infectious disease detection and chronic disease management. Molecular diagnostics, in particular, are gaining traction as they offer high sensitivity and faster turnaround times, which are critical during disease outbreaks.

Hospitals and diagnostic laboratories represent the largest end-user segments, while point-of-care testing is gradually gaining popularity in remote and underserved areas.

Get instant access to a free sample report complete with the full TOC.

Competitive Landscape

The MEA in-vitro diagnostics market is moderately competitive, with global players focusing on regional expansion, partnerships, and product localization. Key companies operating in the market include:

Becton, Dickinson and Company

Beckman Coulter, Inc.

Bio-Rad Laboratories, Inc.

Surmodics IVD, Inc.

Illumina, Inc.

Others

These companies are leveraging technological innovation and distribution networks to strengthen their presence across the region.